Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 41

  • 1 641 clinical trials
  • 555 recruiting
  • 290 conditions
  • 28 countries

Conditions in this area

290 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma88Dermatitis atopic88HIV infection75Rheumatoid arthritis75Systemic lupus erythematosus61Multiple sclerosis59Psoriasis53Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Type 1 diabetes mellitus38Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Cardiac amyloidosis29Sjogren's syndrome29Interstitial lung disease28Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy23Vitiligo23Hereditary angioedema22Axial spondyloarthritis21+266

Clinical trials in Immune system disorders

1 641 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 641 clinical trials

Lung transplant rejection

Recruiting

Study on the Effectiveness of Belumosudil and Azithromycin for Adults with Chronic Lung Rejection After Lung Transplant

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Belumosudil Mesilate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Encephalitis autoimmune

Recruiting

Study on the Effects and Safety of Inebilizumab for Patients with Anti-NMDA Receptor Encephalitis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cetirizine
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Interstitial lung disease

Recruiting

Study on Long-Term Safety of Inhaled Treprostinil for Patients with Fibrotic Lung Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Treprostinil
  • Sponsor:United Therapeutics Corp.

Dermatomyositis+1

Recruiting

Study on the Effectiveness of Dazukibart in Adults with Active Dermatomyositis or Polymyositis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Pfizer Inc.

B-cell lymphoma+1

Recruiting

Long-term Study of Ibrutinib for Patients with B-cell Non-Hodgkin's Lymphoma and Chronic Graft Versus Host Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Janssen Cilag International

Uveitis

Recruiting

Study Comparing Adalimumab and Mycophenolate Mofetil for Patients with Steroid-Dependent Non-Infectious Uveitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic scleroderma

Recruiting

Study on the Use of Allogenic Adipose-Tissue-Derived Mesenchymal Stem Cells for Healing Chronic Digital Ulcers in Systemic Sclerosis Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Anti-myelin-associated glycoprotein associated polyneuropathy

Recruiting

Study on Zanubrutinib and Rituximab for Patients with IgM Monoclonal Gammopathy and MAG Antibodies-Related Polyneuropathy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zanubrutinib
  • Sponsor:Universitair Medisch Centrum Utrecht

IgA nephropathy

Recruiting

Study on the Long-term Safety and Effectiveness of Sibeprenlimab for Patients with Immunoglobulin A Nephropathy (IgAN)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Hereditary angioedema

Recruiting

Long-Term Safety Study of NTLA-2002 for Patients with Hereditary Angioedema, Using Messenger RNA Encoding Cas9 and HU-G012267

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Lonvoguran
  • Sponsor:Intellia Therapeutics Inc.

Systemic lupus erythematosus

Recruiting

Study of Anifrolumab for Children and Teens with Moderate to Severe Lupus

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

HIV infection

Recruiting

Study on the Effectiveness of Doravirine, Tenofovir Disoproxil, and Lamivudine in HIV Patients with M184V/I Mutation and Controlled Viral Load

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine39 clinical trialsTocilizumab38 clinical trialsTenofovir Alafenamide37 clinical trialsMethotrexate36 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.